Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497042 | 0.92 | SMO (0.49) | SMONR3C1 | |
| SCHEMBL6489905 | 0.85 | PPARG (0.46) | L3MBTL1RAB9ANPC1SMN1; SMN2GCGR | |
| SCHEMBL6493468 | 0.84 | GCGR (0.39) | L3MBTL1RAB9ANPC1SMN1; SMN2GCGR | |
| SCHEMBL6489227 | 0.84 | CTNNB1 (0.48) | L3MBTL1RAB9ANPC1SMN1; SMN2TAS1R3 | |
| SCHEMBL6490155 | 0.83 | L3MBTL1 (0.47) | L3MBTL1RAB9ANPC1SMN1; SMN2HTT | |
| SCHEMBL6490419 | 0.83 | L3MBTL1 (0.46) | L3MBTL1RAB9ANPC1SMN1; SMN2GCGR | |
| SCHEMBL6501179 | 0.81 | SYK (0.47) | L3MBTL1RAB9ANPC1SMN1; SMN2GCGR | |
| SCHEMBL6498069 | 0.81 | HDAC7 (0.49) | L3MBTL1RAB9ANPC1SMN1; SMN2TAS1R3 | |
| SCHEMBL6792560 | 0.80 | SMO (0.57) | KDRSMONR3C1 | |
| SCHEMBL6488546 | 0.80 | CTNNB1 (0.54) | L3MBTL1RAB9ANPC1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | L3MBTL1 2276/4885RAB9A 4382/4885NPC1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.